THIS MUTATED INFLUENZA VIRUS CAN BE TREATED IN PH1-2 . TO CHECK THE LYSIS OF THE VIRUS SIMULATING THE INTERFERON ACTIVITY HAS TO BE DONE SIMULTANEOUSLY.

1. ADVERSE CONDITON PROVIDED FOR
INFLUENZA VIRUS (MUTATED
STRAIN TOO-CORONA)
DR.SREEREMYA
FACULTY OF BIOLOGY

2. • Corona virus is a positive stranded RNA Virus
• It is apndemic
• The action was first found in china , then
transferred to belgium, when the first time
attack occurred.

3. • Corona virus(COVID-19) is RNA virus. Which has
proved to be pandemic.It causes respiratory
disease called Severe Acute Respiratory
Syndrome(SARS). Currently it is a deadly disease
which is killing hundreds of people day by day
from late 2019 to till date. There is only few
studies regarding the corona virus infection in
animals. Studies are still progressing to find
remedies like variolation, RNA silencing or
boosting human interferon’s to decrease the
affect of the disease.

4. • THEORETICAL OUTLOOK-Corona virus action
initates and spreads as droplets enters the
mouth, nose or lacrimal gland of eyes.
• The major clinical manifestation is it causes
cold, fever, flu, then bronchitis, chances of
pneumonia and lung disorder

5. • THIS MUTATED INFLUENZA VIRUS CAN BE
TREATED IN PH1-2 . TO CHECK THE LYSIS OF
THE VIRUS
• SIMULATING THE INTERFERON ACTIVITY HAS
TO BE DONE SIMULTANEOUSLY.

6. • Researchers don’t yet understand the key particulars of
how this virus spreads, coronaviruses usually spreads
through droplets containing large particles that typically
can only be suspended in the air for three to the six feet
before dissipating. By contrast, measles or varicella
(chickenpox) spread through the smaller droplets over
much greater distances. Some coronaviruses also have
been found in the stool of certain individuals in few cases.
• So it’s likely that coughs or sneezes from an infected person
may also spread the virus. It’s too early to say whether
another route of the transmission, fecal-oral contact, might
also spreads this particular virus(Lucas et al.,1978).

7. REFERNCES
• Rovozzo, G. & Burke, C. A Manual of Basic Virological Techniques (Prentice-Hall, 1973).
• 2. Leland, D. & Ginocchino, C. Role of Cell Culture for Virus Detection in the Age of Technology. Clin
• Microbiol Rev 20, 49-78 (2007).
• 3. Cohen, J.I. Epstein-Barr virus infection. N Engl J Med 343, 481-92 (2000).
• 4. Gotoh, K. et al. Replication of Epstein-Barr virus primary infection in human tonsil tissue explants. PLoS
• One 6, e25490.
• 5. Mahy, B. & Kangro, H. Virology Methods manual (Academic Press, 1996).
• 6. Reed, L. & Muench, H. A simple method of estimating fifty percent endpoints. American Journal of
• Hygiene 27, 493-497 (1938).
• 7. McLimans, W. (eds. Rothblat, G. & Cristofalo, V.) (Academic Press, New York, 1972).
• 8. Shipman, C., Jr. Evaluation of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) as a tissue
• culture buffer. Proc Soc Exp Biol Med 130, 305-10 (1969).
• 9. Giandomenico, A.R., Cerniglia, G.E., Biaglow, J.E., Stevens, C.W. & Koch, C.J. The importance of sodium
• pyruvate in assessing damage produced by hydrogen peroxide. Free Radic Biol Med 23, 426-34 (1997).
• 10. Jacoby, W. & Pasten, I. (Academic Press, New York, 1979).
• 11. Mazur, P. The role of intracellular freezing in the death of cells cooled at supraoptimal rates. Cryobiology
• 14, 251-72 (1977).
• 12. Mazur, P. Cryobiology: the freezing of biological systems. Science 168, 939-49 (1970).
• 13. Fahy, G.M. The relevance of cryoprotectant "toxicity" to cryobiology. Cryobiology 23, 1-13 (1986).
• 14. Meryman, H.T. Cryoprotective agents. Cryobiology 8, 173-83 (1971).
• 15. Rowe, T.W. Optimization in freeze-drying. Dev Biol Stand 36, 79-97 (1976).
• 16. Heckly, R. Principles of preserving bacteria by freeze-drying. Dev Ind Microbiol 26, 379-395 (1985).
• 17. United States Department of Health and Human Serves, C.f.D.C., and National Institutes of Health.
• Biosafety in Microbiological and Biomedical Laboratories (U.S. Government Printing Office, HHS
• Publication No. (CDC) 21-1112, Washington DC, 2009).
• 18. Enders, J.F. Cytopathology of virus infections: particular reference to tissue culture studies. Annu Rev
• Microbiol 8, 473-502 (1954).
• 19. Jha, K.K., Banga, S., Palejwala, V. & Ozer, H.L. SV40-Mediated immortalization. Exp Cell Res 245, 1-7 (1998).
• 20. Kirchhoff, C. et al. Immortalization by large T-antigen of the adult epididymal duct epithelium. Mol Cell
• Endocrinol 216, 83-94 (2004).
• 21. Mancheno-Corvo, P. & Martin-Duque, P. Viral gene therapy. Clin Transl Oncol 8, 858-67 (2006).
• 22. Miedzybrodzki, R. et al. Clinical aspects of phage therapy. Adv Virus Res 83, 73-121.
• 23. Kropinski, A.M. Phage Therapy - Everything Old is New Again. Can J Infect Dis Med Microbiol 17, 297-306
• (2006).
• International Journal of Computational Intelligence, Biotechnology and Biochemical Engineering, Epidemology of Nipah Virus –Review, S. Sreeremya,2018.vol2(2):1-4.